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Abstract 
Background and study aims: Understanding patients’ experience of screening programmes 
is crucial for service improvement. The English Bowel Cancer Screening Programme 
(BCSP) aims to achieve this by sending out questionnaires to all patients who undergo a 
colonoscopy following an abnormal faecal occult blood test result. This study used the 
questionnaire data to report experiences of these patients. 
Patients and methods: Data on patients who underwent colonoscopy between 2011 and 
2012 were extracted from the BCSP database. Descriptive statistics summarised key 
questionnaire items related to informed choice, psychological wellbeing, physical 
experience, and after-effects. Multilevel logistic regression was used to test for associations 
with variables of interest: gender, age, socioeconomic status, colonoscopy results, and 
screening centre performance (adenoma detection rate, caecal intubation rate, proportion of 
colonoscopies involving sedation).  
Results: Data from 50,858 patients (79.3% of those eligible) were analysed. The large 
majority reported a positive experience on items relating to informed choice (e.g. 95.7% felt 
they understood the risks) and psychological wellbeing (e.g. 98.3% felt treated with respect). 
However, an appreciable proportion experienced unexpected test discomfort (21.0%) or pain 
at home (14.8%). There were few notable demographic differences although women were 
more likely to experience unexpected discomfort (25.1% vs. 18.0%; p<0.01) and pain at 
home (18.2% vs 12.3%; p<0.01). No associations were apparent with centre-level variables. 
Conclusions: Colonoscopy experience is generally positive, suggesting high satisfaction with 
the BCSP. Reported pain and unexpected discomfort are more negative than most other 
outcomes (particularly for women); measures to improve this should be considered. 
 
  
Introduction 
The National Health Service (NHS) Bowel Cancer Screening Programme (BCSP) in England 
was initiated in light of strong evidence that screening is effective in reducing colorectal 
cancer (CRC) mortality when individuals aged 60-74 years are offered a biennial guaiac 
Faecal Occult Blood test (gFOBt) and those who receive an abnormal result are offered a 
colonoscopy [1,2,3]. As a matter of routine, the BCSP posts a questionnaire to all individuals 
who undergo colonoscopy, asking about their experience. The national scale of the 
programme means that a large volume of patient experience data is collected. 
The systematic assessment of patients’ experience of healthcare is an increasingly 
important part of refining quality and effectiveness of service delivery [4]. Data on patients’ 
experience can be used to identify aspects of a service that warrant improvement, that are 
poorer for particular subgroups of patients, or that are associated with markers of clinical 
performance, which allows for more effective allocation of resources. Measures of patients’ 
experience have been used in a diverse range of contexts including general practice [5], 
elective surgery [6], and chronic heart failure [7], and have recently been incorporated into 
measures of quality in the NHS in England [8]. Screening programmes like the BCSP can 
use routinely collected data to highlight potential improvements and inform other screening 
programmes. For example, programme data has been used to understand how adjusting the 
threshold for categorising a gFOBt sample as ‘abnormal’ would affect cancer detection rates 
and colonoscopy activity [9]. Evaluating questionnaire data would help devise methods of 
improvement and strategic planning in the domain of patients’ experience as well.  
We describe patients’ experience of colonoscopy over two years of the English BCSP using 
routinely recorded patient-reported data. Questionnaire items considered particularly 
important were those related to informed choice, psychological wellbeing, physical 
experience, and after-effects of the colonoscopy procedure. We also compare experience 
between demographic subgroups (gender, age, area-level socioeconomic deprivation), 
screening results, and centre-level variables (adenoma detection rates, caecal intubation 
rates, proportion of colonoscopies involving any sedation use at investigating hospitals) in 
order to explore potentially important associations. 
Method 
Participants 
The organisation and screening pathway used by the English BCSP is reported in detail 
elsewhere [2,3]. In brief, individuals in the eligible age range and registered at any General 
Practice are invited to undertake gFOBt at home and then return it by post to a laboratory at 
one of five “Screening Hubs” for analysis. Individuals older than 74 years are also able to 
participate by manually requesting a kit. Participants receiving an abnormal gFOBt result are 
invited to one of 62 “Screening Centres” (59 existed during the study period) for an 
appointment with a Specialist Screening Practitioner (SSP), who assesses suitability for 
colonoscopy, explains the procedure, and answers questions. Centres are also where 
colonoscopies ultimately take place. The BCSP began rollout in 2006 and the process was 
completed in 2010. As of December 2014, the BCSP had invited over 24 million people, 
received over 25.7 million test kits, which precipitated over 272,000 colonoscopies (Bowel 
Evaluation Group, February, 2015, personal communication). 
The sampling population consisted of all patients who underwent colonoscopy following an 
abnormal gFOBt result in the English BCSP and were sent a questionnaire. Data were 
extracted for all such procedures between 1st January 2011 and December 31st 2012 (i.e. 
two full years after completion of the programme’s rollout in 2010). Completion and return of 
the questionnaire indicated implied consent to participate in this service evaluation [10]. 
Ineligible patients were excluded based on the following criteria: i) tested outside the date 
range of interest; ii) undergoing surveillance rather than screening; iii) did not receive 
colonoscopy, iv) experienced an administrative error with their questionnaire; v) investigated 
at more than one centre or had no centre recorded; vi) did not have a screening result (i.e. 
the most severe test result that a patient received during their screening episode, ranging 
from cancer to a normal result); vii) did not have postcode data (necessary for determining 
area-level socioeconomic deprivation; described below). 
Based on guidance from the Health Research Authority, Research Ethics Committee 
approval was deemed unnecessary for this service evaluation [11]. Permission was granted 
to access anonymised data by the English Bowel Cancer Screening Research Committee. 
Procedures 
Colonoscopy is performed to nationally mandated standards; all colonoscopists are required 
to demonstrate experience, knowledge, and competence in order to achieve accreditation [3] 
[12]. Performance of colonoscopists within the BCSP is also monitored via several key 
metrics, such as adenoma detection rates and caecal intubation rates. Previous research 
has found high levels of both quality and safety [3]. All patients were provided with one of 
several forms of bowel preparation (per centre preference). 
Measures 
The precise number of questionnaire items varies depending on whether patients’ episodes 
were for screening or surveillance (i.e. following previous removal of adenomas), and 
whether they had endoscopic or radiological testing, or both. The most commonly used 
questionnaire (for screening patients who underwent colonoscopy alone) consists of 35 
items (Appendix 1). The alternative questionnaire applicable to this study (for screening 
patients who received both colonoscopy and radiological tests) consists of 52 items; most 
items relating to the radiological test are identical to those for the endoscopic test (Appendix 
2). Most items are answered on either a 5-point Likert scale ranging from “strongly agree” to 
“strongly disagree” (e.g. “I felt I had an understanding of the risks of having a colonoscopy”) 
or via 2 or 3 response options (“yes”, “no”, “don’t remember”; e.g. for “During the 
colonoscopy, I asked for it to be stopped or paused”).  
The questionnaire assesses experience that is relevant to several key concerns regarding 
service delivery. Colonoscopy should cause as little pain and discomfort as possible and so 
two items measure unexpected discomfort during the test and whether it was stopped or 
paused. Data are also collected regarding bleeding and pain after going home. Since 
patients’ experience is affected by more than the physical aspects of the investigation [13], 
measures of psychological wellbeing are included, such as whether patients felt they were 
treated with respect and given sufficient privacy at the hospital. Furthermore, the National 
Screening Committee has set a policy goal of ensuring that invitees make an informed 
choice before undergoing the test [14]. Consequently, the questionnaire also asks patients 
whether they felt they understood the risks and benefits, and whether they were given clear 
information regarding the bowel preparation. These ten questions (relating to the four topics 
of interest) were selected for analysis, following discussion between the authors regarding 
the items that were expected to be the most valid and important to patients’ experience 
(Table 3). 
In addition to questionnaire data, the Bowel Cancer Screening System (BCSS) records 
demographic information on patients’ age, gender and postcode. The latter was used to 
derive an area-level measure of socioeconomic deprivation (Index of Multiple Deprivation; 
IMD) using an online tool (GeoConvert) [15]. IMD scores consist of a composite measure of 
education, income, housing, health and environment; higher scores represent greater 
deprivation [16]. The BCSS records details of previous screening participation, test results, 
and the centre at which patients were investigated. Centre-level data on the proportion of 
colonoscopies during which sedation was administered (either intravenously or nitrous oxide 
and oxygen), adenoma detection rates, and caecal intubation rates were also available. 
Questionnaires are prepared with patients’ NHS Numbers (but no other identifying 
information) before they are disseminated, which allowed these fields were to be extracted 
from the BCSS for all patients investigated during the date range of interest and matched 
with questionnaire data. 
Analysis 
Data cleaning, recoding and analysis used SPSS 22 for Windows (IBM, Armonk, NY, USA) 
and R 3.0.1 for Mac OS X (R Foundation for Statistical Computing, Vienna, Austria). For 
patients responding to at least one item, missing data were addressed using 10 multiple 
imputations under the missing at random assumption [17] as part of a parallel study 
comparing patients’ experience of colonoscopy and Computed Tomographic colonography 
(submitted). The imputation models used fully conditional specification, with predictive mean 
matching for continuous variables, ordered logistic regression for ordinal variables and 
multinomial logistic regression for categorical variables. Imputation models included patient 
age, gender, IMD, screening round type (i.e. whether a patient was participating in gFOBt 
screening for the first time or whether they had participated at least once before [18]), test 
type, screening result, and responses to questionnaire items [19]. Model fit was assessed by 
diagnostic plots and comparing imputed and non-imputed data via worm plots to estimate 
distributional discrepancy. 
The analysis consisted of four components: i) testing whether patient-level variables were 
associated with (non-)response to the questionnaire; ii) summarising overall questionnaire 
outcomes; testing whether iii) patient-level and iv) centre-level variables were associated 
with questionnaire outcomes. 
For i), iii), and iv), multilevel logistic regression was used; screening centre was included as 
a higher-level variable to account for possible clustering effects. Odds ratios and p-values 
(adjusted, based on all independent variables) are reported alongside crude overall 
proportions (e.g. the proportions of men and women responding to the questionnaire). For i) 
and iii), patient-level independent variables consisted of gender, age, IMD, and screening 
result. Screening round type was incorporated as a covariate. Participant-reported sedation 
use was also added as a covariate for iii) (except when this was an outcome variable). Age 
and IMD were divided into tertiles to facilitate interpretation. 
For ii), descriptive statistics were used to summarise crude overall imputed proportions of 
participants (strongly) agreeing or stating ‘yes’ for each of the 10 questionnaire items. These 
also comprised the outcomes for iii). For analyses of associations between questionnaire 
items and screening result (in iii) or centre-level variables (in iv), outcomes consisted of the 
four that were considered most likely to be related (Table 6). 
For iv), available centre-level independent variables were first summarised using descriptive 
statistics. Models were then constructed for each of the four relevant questionnaire items, 
with and without each of the independent variables. A likelihood ratio test was used to test 
whether any improved model fit. In all analyses of imputed data (i.e. ii), iii), and iv), models 
were constructed for each imputation and pooled [20]. 
Results 
Participant characteristics and variables associated with questionnaire response 
Out of the original data extraction of 79,493 patients who were sent the questionnaire, 
64,152 eligible patients remained after exclusions (Table 1), of whom 50,858 responded to 
the questionnaire and were included in the main analysis (79.3%). The final sample 
consisted of 29,792 (58.6%) males, had a median age of 66 years (interquartile range [IQR]: 
63 to 69) and a median IMD score of 14.6 (IQR: 8.6 to 24.6). 22,091 (43.4%) were 
participating in gFOBt screening for the first time. Cancer was diagnosed in 8.3% of 
participants and adenomas were found in a further 43.9% of participants. Patients were 
marginally more likely to respond if they were in an older tertile, living in a less deprived 
tertile, or were diagnosed with adenomas rather than cancer (differences between 
categories were no more than 9.2%; p<.01). Full results for the analysis of associations with 
whether patients responded to the questionnaire are reported in Table 2. 
Overall questionnaire outcomes 
For the individuals who had responded to at least one questionnaire item, further missing 
data were minimal, ranging from 1.4% to 2.7% of participants for each variable (i.e. if 
participants responded to the questionnaire at all, they usually completed every item). 
Consequently, the imputed models were considered realistic and highly plausible. 
Responses to items relating to informed choice were almost always positive for all three 
relevant items. The overall imputed percentages of participants (strongly) agreeing that they 
had an understanding of the risks and benefits were 95.7% and 98.2%, respectively. With 
respect to information about bowel preparation, 97.8% of participants felt it was clear. 
Responses were also nearly unanimous for items on psychological wellbeing. 98.3% of 
participants stated that they were treated with respect and 97.9% endorsed the item on 
whether their privacy was maintained. Experience was notably more mixed in terms of items 
on physical discomfort: 21.0% of participants experienced more discomfort than expected 
and 5.1% asked for the colonoscopy to be stopped/paused. Use of sedation was reported by 
79.1% of participants. It was also not uncommon for participants to report pain after going 
home (14.8%), or bleeding after going home (7.6%).  
Exploratory subgroup analyses – associations between experience and demographics or 
screening results 
Demographic characteristics were statistically significantly associated with various aspects 
of participants’ experience. In several cases, this corresponded with moderately large 
adjusted odds ratios (e.g. of agreeing or strongly agreeing with questionnaire items for males 
vs. females) and appreciable absolute differences between demographic characteristics.  
Specifically, in the case of gender, women were more likely to report unexpected discomfort 
(crude imputed proportions: 25.1% vs. 18.0%), to report receiving sedation (86.7% vs. 
73.6%), to ask for the test to be stopped/paused (6.8% vs. 3.9%), and to report pain after 
going home (18.2% vs. 12.3%). Furthermore, in analyses of age, >64 to 68 year old 
participants and >68 to 93 year old participants were slightly less likely to report pain after 
going home (13.8% and 12.8%, respectively) compared to 59 to 64 year old participants 
(16.9%). Finally, individuals in the most socioeconomically deprived tertile were slightly more 
likely to report unexpected discomfort (23.0%) than in the least deprived tertile (19.5%). This 
was also the case for pain after going home (16.1% vs. 13.6%). Participants in the most 
deprived tertile were also less likely to report sedation administration than those in the least 
deprived tertile (75.8% vs. 81.2%). There were few meaningful associations between 
screening results and the four outcomes of interest. Compared with the reference group of 
participants diagnosed with cancer, participants diagnosed with high-risk adenomas were 
more likely to report pain after going home (18.6% vs. 15.0%). In addition, participants with 
adenomas (low-, intermediate-, or high-risk) or normal results were less likely to report 
bleeding after going home compared to participants diagnosed with cancer (3.3 to 11.2% vs. 
15.1%).  
Crude imputed proportions of participants (strongly) agreeing or responding “yes” to the 
main outcomes of interest are reported by gender (Table 3), age tertiles (Table 4), IMD 
tertiles (Table 5), and screening results (Table 6) along with adjusted odds ratios, 95% 
confidence intervals (CIs) and p-values (also for imputed sample data). 
Exploratory subgroup analyses – centre level associations with experience 
The three centre-level variables included in this analysis were adenoma detection rate 
(median percentage across all centres: 47.8%; IQR: 44.4% to 50.1%), caecal intubation rate 
(median: 95.4%; IQR: 93.9% to 96.5%), and proportion of colonoscopies involving sedation 
(median: 92.5%; IQR: 81.8% to 97.9%). No associations were found between any of the 
centre-level variables and the four outcomes of interest. Given that missing data were 
minimal, results of analyses on non-imputed data are not reported since they did not differ 
meaningfully for any models. 
Discussion 
Patient experience is a fundamental element of healthcare delivery [21] and should be a 
priority in screening programmes. Previous comparable studies of patients’ experience of 
colonoscopy using the Global Rating Scale have been relatively small, limited to a subset of 
national endoscopy departments, and not necessarily specific to a screening context [22,23]. 
In contrast, this study comprised a large sample of patients investigated with colonoscopy 
following an abnormal gFOBt result, making this one of the largest studies of patient 
experience in the context of cancer screening. The response rate was high and similar to 
comparable previous research [24], meaning that the results are likely to be highly 
representative and applicable to the target population. We found that experience was 
positive for most participants for most items assessed. With respect to items relating to 
feeling informed, the overwhelming majority of participants reported understanding the risks 
and benefits of colonoscopy, and agreed that information for bowel preparation was clear. 
This suggests that participants were satisfied with the information provided by leaflets and 
screening practitioners. It was also reassuring that there were no large social disparities (in 
terms of deprivation, gender or age) on these items. This provides some evidence that 
participants across all demographic groups felt well-informed about the test [25,26,27]. 
However, it is important to remain cautious about making any inferences about the extent to 
which these participants made an informed choice to undergo colonoscopy. By definition, 
objective understanding is a more relevant facet of ‘informed’ choice than subjective 
understanding [28] and the available measures only assess the latter. Previous research has 
found that patients’ overall knowledge of colonoscopy (as a first-line screening test in the 
US) is generally low, even after discussion with a clinician [29] and the very high proportion 
of participants who reported that they felt they had an understanding may be an indication 
that they had overestimated their knowledge. 
The large majority of participants’ also reported a positive experience in terms of their 
psychological wellbeing at the hospital, with most participants agreeing that they felt they 
were treated with respect and given enough privacy. In some respects, this corresponds with 
previous findings that embarrassment during colonoscopy is generally minimal [24]. There 
were no meaningful differences observed between men and women; this is reassuring given 
previous research suggesting that feelings of vulnerability and embarrassment are more 
common in women [13].  
In relation to the colonoscopy experience itself, results were more mixed. Although only a 
small proportion asked for the procedure to be stopped/paused (5.1%), approximately 1 in 5 
participants reported experiencing more discomfort than they had expected. Furthermore, in 
terms of after-effects, 14.8% reported pain after going home. Women were more likely to 
report both unexpected discomfort and pain at home than men, which adds to previous 
research indicating that women report greater overall levels of pain and discomfort during 
the colonoscopy procedure itself [30,31]. Previously suggested reasons include colonoscopy 
being more technically difficult in women due to greater colonic length [32] and also lower 
pain thresholds in women [33]. In addition to pain, women were slightly more likely to report 
bleeding after going home, meaning they represent a group for whom there is likely to be 
greater scope to improve experience.  
Pain after going home was also reported slightly more often in younger participants. As with 
women, greater overall discomfort and pain has previously been observed for younger 
patients during colonoscopy itself [30]. Possible reasons include decreasing perceptions of 
pain with age [34] but also greater stoicism or reluctance to rate healthcare negatively in 
older patients [35]. However, there is limited evidence to support these possibilities, which 
should also be interpreted in the context of the small absolute differences observed here. 
Although it was unsurprising that participants diagnosed with cancer were more likely to 
report bleeding than participants with adenomas or normal results, the finding that 
participants diagnosed with high-risk adenomas were more likely to report pain after going 
home than participants diagnosed with cancer was somewhat more unexpected. This may 
reflect differences in therapeutic approaches: removal of a high-risk (i.e. relatively large) 
adenoma entails a more protracted process involving insufflation with greater potential for 
pain in comparison to a biopsy, which is the more likely intervention when a cancer is 
observed. 
The overall levels of unexpected discomfort suggest that the counselling patients receive 
from SSPs prior to the procedure could be improved and this may be particularly true for 
more deprived individuals and women. It also emphasises the need for endoscopists to 
attend to patients’ physical well-being during the procedure in order to minimise discomfort 
and pain. Carbon dioxide insufflation is not mandated within the programme but widespread 
utilisation may reduce the prevalence of pain after going home, in addition to post-procedural 
advice on pain management. 
We found no associations in terms of centre-level adenoma detection rates, caecal 
intubation rates, or proportion of colonoscopies involving sedation and potentially related 
outcomes. For some independent variables, this was not surprising since there was little 
variance (e.g. caecal intubation rates were high and IQR was narrow). However, only centre-
level data were available, rather than endoscopist- or patient-level data, so these findings 
should be interpreted with appropriate caution. 
A limitation related to the large sample was that absolute differences between comparator 
and reference groups in subgroup analyses were often marginal and unlikely to be of 
practical importance, despite small p-values and moderately large odds ratios. For example, 
after adjusting for possible confounding variables, the odds ratio for females vs. males 
(strongly) agreeing that they understood the risks of having a colonoscopy was 0.83 (95% 
CI: 0.76 to 0.91; p<.0005), which corresponds to an absolute difference of only 0.7% (95.3% 
vs. 96.0%). As a result, we focused our interpretation on the largest differences that we 
judged most likely to be clinically important. Further limitations relate primarily to 
shortcomings of the questionnaire. For example, although unexpected discomfort is 
measured, patients are not able to report the absolute degree of discomfort or pain 
experienced during the procedure. Moreover, the item relating to whether the colonoscopy 
was stopped/paused does not allow patients to distinguish between the two, despite the 
substantially different implications (a diagnostic test with longer duration vs. an incomplete 
one).  
In addition to the inability of the questionnaire to assess informed choice objectively, it does 
not assess patients’ views on the decision-making process for colonoscopy. There is 
evidence that only a small proportion of patients would prefer to make a completely 
autonomous decision for first-line gFOBt screening, while the majority would prefer guidance 
or a recommendation from a clinical authority [36]. It is unclear to what extent patients felt 
they were encouraged to participate in a process of shared decision-making by the SSP and 
whether this matched their preferences. 
More generally, the questionnaire is not validated and so items reported here were selected 
on the basis of our subjective judgements regarding which items had superior face validity 
and relevance to patients. Although this resulted in a pool of items that assessed a wide 
range of topics, the questionnaire is likely to omit important aspects of patients’ experience 
(in addition to those already suggested). For example, the questionnaire does not assess 
experience of bowel preparation, which has been found to be the worst part of whole-colon 
testing [24] [37,38]. Another notable omission is the lack of items relating to the extent of any 
interruption to daily routine [24]. 
There are established methods of developing psychometrically sound measures of patients’ 
experience. For example, interviews and discussion groups involving patients who have 
undergone the test can be used to compile a pool of potentially relevant items [39,40]. This 
provisional set can then be piloted as a questionnaire in order to determine a final measure 
that is both reliable and valid. However, it is unclear what the development process was for 
the current questionnaire and whether any patient input went into producing it. A previous 
review found that measures are often limited by a lack of patient involvement to determine 
key determinants of their experience [41] and clinicians are often poor at judging what these 
determinants are [39] [42]. It is highly likely that these limitations also apply to the current 
questionnaires. Hence, a rigorously designed Patient-Reported Experience Measure 
(PREM) is likely to be able to make a greater contribution to service delivery than the 
existing ad-hoc measure. 
In conclusion, the large majority of self-reported experience of colonoscopy is positive on 
key outcomes in the existing questionnaire. Although it would be beneficial to revise the 
questionnaire so that it more accurately and completely assesses patients’ experience, data 
from the existing questionnaire highlights scope for improvement in several areas. It may be 
possible to more effectively assess and manage patients’ expectations regarding possible 
levels of discomfort during colonoscopy, for endoscopists to further reduce discomfort during 
the procedure itself, and to provide more advice on managing pain after patients have gone 
home (including information regarding support available after the test). Such interventions 
may be particularly effective for women, younger patients and individuals that are more 
deprived.  
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Tables 
Table 1 - Numbers and percentages of patients excluded from the original extraction of 79,493 patients 
Reason for exclusion n (%) 
Tested for the purpose of adenoma surveillance, not screening 12,316 
Did not receive colonoscopy 1,876 
Tested outside applicable date range 920 
Did not have IMD data 106 
Administrative error with the questionnaire 76 
Investigated at more than one centre or had no centre record 46 
Did not have most severe test result data 1 
Total excluded 15,341 
 
 
 
 
 
 
 
 
 
Table 2 – Analysis of variables potentially associated with whether patients responded to the questionnaire (p-values <0.01 are in bold) 
Independent variable 
Crude overall n (%) 
not responding / responding 
Variable level vs. reference category 
 
Non-responders 
(n=13,294) 
Responders 
(n=50,858) 
Adjusted OR 
(95% CI) 
p-value 
Gender       
Females 5,778 21.5 21,066 78.5 0.95 (0.91 to 0.99) 0.01 
Males (reference category) 7,516 20.1 29,792 79.9   
Age       
>68-93 years 3,280 18.0 14,935 82.0 1.30 (1.24 to 1.37) <0.01 
>64 to 68 years 3,824 19.5 15,807 80.5 1.14 (1.08 to 1.20) <0.01 
59 to 64 years (reference category) 6,190 23.5 20,116 76.5   
IMD* tertiles       
High 4,441 26.0 12,667 74.0 0.64 (0.60 to 0.67) <0.01 
Medium 4,815 20.9 18,263 79.1 0.84 (0.79 to 0.88) <0.01 
Low (reference category) 4,038 16.8 19,928 83.2   
Screening result       
High-risk adenoma 1,133 18.8 4,905 81.2 1.30 (1.18 to 1.43) <0.01 
Intermediate-risk adenoma 1,658 17.2 7,990 82.8 1.41 (1.30 to 1.54) <0.01 
Low-risk adenoma 2,452 20.6 9,438 79.4 1.13 (1.04 to 1.23) <0.01 
Abnormal (no histology) 65 27.2 174 72.8 0.77 (0.57 to 1.04) 0.09 
Abnormal 4,000 20.6 15,456 79.4 1.10 (1.02 to 1.19) 0.01 
Normal (no abnormalities detected) 2,802 24.4 8,690 75.6 0.98 (0.91 to 1.07) 0.69 
Cancer (reference category) 1,184 22.0 4,205 78.0   
IMD: Index of Multiple Deprivation; OR: Odds ratio; CI: Confidence interval 
Covariates: Screening round type; Screening centre (as a higher-level variable) 
 
 
 
 
Table 3 – Analysis of imputed questionnaire responses by gender (p-values <0.01 are in bold) 
Item 
Crude overall n (%) 
agreeing / strongly agreeing / stating yes 
Females vs. males 
 
Males 
(n=29,792) 
Females 
(n=21,066) 
Adjusted OR 
(95% CI) 
p-value 
Informed choice       
I felt I had an understanding of the risks of 
having a colonoscopy 
28,593 96.0 20,073 95.3 0.83 
(0.76 to 0.91) 
<0.01 
I felt I had an understanding of the benefits 
of having a colonoscopy 
29,301 98.4 20,652 98.0 0.81 
(0.70 to 0.93) 
<0.01 
I was given clear information on how to take 
the bowel prep medicine (laxative) 
29,185 98.0 20,579 97.7 0.87 
(0.76 to 0.99) 
0.04 
Psychological wellbeing       
I feel I was treated with respect during my visit 
to the hospital 
29,323 98.4 20,694 98.2 0.89 
(0.77 to 1.03) 
0.12 
I feel that my privacy was maintained as much 
as possible during my visit to the hospital 
29,115 97.7 20,663 98.1 1.20 
(1.05 to 1.37) 
0.01 
Physical aspects of colonoscopy       
The colonoscopy was more uncomfortable 
than I expected 
5,376 18.0 5,290 25.1 1.62 
(1.55 to 1.70) 
<0.01 
I was given sedation for my colonoscopy 
(sedation is a drug to make you feel relaxed) 
21,940 73.6 18,272 86.7 2.49 
(2.37 to 2.62) 
<0.01 
During the colonoscopy, I asked for it to be 
stopped or paused 
1,159 3.9 1,441 6.8 1.97 
(1.81 to 2.14) 
<0.01 
Colonoscopy after-effects       
After going home, I suffered from pain in my 
bottom and/or stomach 
3,671 12.3 3,838 18.2 1.70 
(1.62 to 1.80) 
<0.01 
After going home, I had bleeding from my 
bottom 
2,432 8.2 1,432 6.8 0.92 
(0.86 to 0.99) 
0.03 
Covariates: Screening round type; Sedation use (except where this was the outcome); Screening centre (as a higher-level variable) 
 
 
 
Table 4 – Analysis of imputed questionnaire responses by age tertiles (p-values <0.01 are in bold) 
Item 
Crude overall n (%) 
agreeing / strongly agreeing / stating yes 
>64-68 vs. 59-64 >68-93 vs. 59-64 
 
59-64 
(n=20,116) 
>64-68 
(n=15,807) 
>68-93 
(n=14,935) 
Adjusted OR 
(95% CI) 
p-value 
Adjusted OR 
(95% CI) 
p-value 
Informed choice           
I felt I had an understanding of the risks of 
having a colonoscopy 
19,252 95.7 15,154 95.9 14,261 95.5 0.99 
(0.89 to 1.10) 
0.39 0.92 
(0.82 to 1.02) 
0.12 
I felt I had an understanding of the benefits 
of having a colonoscopy 
19,751 98.2 15,544 98.3 14,658 98.1 1.03 
(0.87 to 1.22) 
0.38 0.92 
(0.78 to 1.09) 
0.24 
I was given clear information on how to take 
the bowel prep medicine (laxative) 
19,646 97.7 15,489 98.0 14,629 98.0 1.17 
(1.01 to 1.37) 
0.05 1.13 
(0.97 to 1.32) 
0.11 
Psychological wellbeing           
I feel I was treated with respect during my visit 
to the hospital 
19,731 98.1 15,537 98.3 14,750 98.8 1.09 
(0.93 to 1.29) 
0.22 1.50 
(1.24 to 1.81) 
<0.01 
I feel that my privacy was maintained as much 
as possible during my visit to the hospital 
19,594 97.4 15,474 97.9 14,710 98.5 1.21 
(1.05 to 1.41) 
0.01 1.69 
(1.43 to 2.00) 
<0.01 
Physical aspects of colonoscopy           
The colonoscopy was more uncomfortable 
than I expected 
4,337 21.6 3,288 20.8 3,042 20.4 0.96 
(0.91 to 1.02) 
0.16 0.95 
(0.90 to 1.00) 
0.06 
I was given sedation for my colonoscopy 
(sedation is a drug to make you feel relaxed) 
15,740 78.2 12,484 79.0 11,988 80.3 1.02 
(0.96 to 1.08) 
0.34 1.03 
(0.97 to 1.09) 
0.25 
During the colonoscopy, I asked for it to be 
stopped or paused 
1,166 5.8 788 5.0 646 4.3 0.88 
(0.79 to 0.97) 
0.01 0.77 
(0.70 to 0.86) 
<0.01 
Colonoscopy after-effects           
After going home, I suffered from pain in my 
bottom and/or stomach 
3,404 16.9 2,188 13.8 1,917 12.8 0.78 
(0.73 to 0.83) 
<0.01 0.72 
(0.67 to 0.76) 
<0.01 
After going home, I had bleeding from my 
bottom 
1,610 8.0 1,151 7.3 1,102 7.4 0.88 
(0.81 to 0.95) 
<0.01 0.84 
(0.78 to 0.92) 
<0.01 
Covariates: Screening round type; Sedation use (except where this was the outcome); Screening centre (as a higher level variable) 
 
 
Table 5 – Analysis of imputed questionnaire responses by IMD tertiles (p-values <0.01 are in bold) 
Item 
Crude overall n (%) 
agreeing / strongly agreeing / stating yes 
Medium vs. Low High vs. Low 
 
Low 
(n=19,928) 
Medium 
(n=18,263) 
High 
(n=12,667) 
Adjusted OR 
(95% CI) 
p-value 
Adjusted OR 
(95% CI) 
p-value 
Informed choice           
I felt I had an understanding of the risks of 
having a colonoscopy 
19,167 96.2 17,476 95.7 12,023 94.9 0.88 
(0.79 to 0.98) 
0.03 0.77 
(0.68 to 0.87) 
<0.01 
I felt I had an understanding of the benefits 
of having a colonoscopy 
19,597 98.3 17,958 98.3 12,398 97.9 1.01 
(0.86 to 1.18) 
0.40 0.81 
(0.69 to 0.96) 
0.02 
I was given clear information on how to take 
the bowel prep medicine (laxative) 
19,503 97.9 17,863 97.8 12,398 97.9 0.98 
(0.85 to 1.13) 
0.38 1.04 
(0.88 to 1.23) 
0.37 
Psychological wellbeing           
I feel I was treated with respect during my visit 
to the hospital 
19,592 98.3 17,976 98.4 12,449 98.3 1.09 
(0.93 to 1.29) 
0.23 1.04 
(0.87 to 1.25) 
0.36 
I feel that my privacy was maintained as much 
as possible during my visit to the hospital 
19,479 97.7 17,918 98.1 12,381 97.7 1.18 
(1.02 to 1.37) 
0.04 1.02 
(0.87 to 1.19) 
0.39 
Physical aspects of colonoscopy           
The colonoscopy was more uncomfortable 
than I expected 
3,880 19.5 3,878 21.2 29,09 23.0 1.12 
(1.06 to 1.18) 
<0.01 1.24 
(1.17 to 1.32) 
<0.01 
I was given sedation for my colonoscopy 
(sedation is a drug to make you feel relaxed) 
16,190 81.2 14,423 79.0 9,599 75.8 0.93 
(0.88 to 0.98) 
0.01 0.88 
(0.82 to 0.93) 
<0.01 
During the colonoscopy, I asked for it to be 
stopped or paused 
1,007 5.1 929 5.1 664 5.2 0.99 
(0.9 to 1.09) 
0.39 1.00 
(0.9 to 1.12) 
0.40 
Colonoscopy after-effects           
After going home, I suffered from pain in my 
bottom and/or stomach 
2,720 13.6 2,748 15.0 2,041 16.1 1.12 
(1.06 to 1.19) 
<0.01 1.22 
(1.14 to 1.31) 
<0.01 
After going home, I had bleeding from my 
bottom 
1,494 7.5 1,413 7.7 957 7.6 1.04 
(0.96 to 1.13) 
0.23 1.02 
(0.93 to 1.11) 
0.37 
Covariates: Screening round type; Sedation use (except where this was the outcome); Screening centre (as a higher-level variable) 
 
 
Table 6 – Analysis of imputed questionnaire responses by screening results (p-values <0.01 are in bold) 
 Item 
Screening result 
The colonoscopy was 
more uncomfortable than I 
expected 
During the colonoscopy, 
I asked for it to be 
stopped or paused 
After going home, I 
suffered from pain in my 
bottom and/or stomach 
After going home, I had 
bleeding from my bottom 
Cancer detected (n=4,205) 
Reference category 
    
Crude overall n; % 
(Strongly) agreeing or stating yes 
887; 21.1 167; 4.0 633; 15.0 635; 15.1 
     
High-risk adenoma (n=4,905)     
Crude overall n; % 1,091; 22.2 276; 5.6 912; 18.6 549; 11.2 
Adjusted OR (95% CI); p-value 1.15 (1.04 to 1.27); 0.01 1.62 (1.32 to 1.98); <0.01 1.36 (1.22 to 1.53); <0.01 0.70 (0.62 to 0.79); <0.01 
     
Intermediate-risk adenoma (n=7,990)     
Crude overall n; % 1,776; 22.2 434; 5.4 1,265; 15.8 674; 8.4 
Adjusted OR (95% CI); p-value 1.07 (0.98 to 1.17); 0.14 1.39 (1.15 to 1.67); <0.01 1.04 (0.93 to 1.15); 0.33 0.51 (0.45 to 0.57); <0.01 
     
Low-risk adenoma (n=9,438)     
Crude overall n; % 1,887; 20.0 455; 4.8 1,364; 14.4 657; 7.0 
Adjusted OR (95% CI); p-value 0.94 (0.85 to 1.02); 0.14 1.24 (1.03 to 1.50); 0.03 0.93 (0.84 to 1.03); 0.16 0.42 (0.37 to 0.47); <0.01 
     
Abnormal, no histology (n=174)     
Crude overall n; % 73; 42.1 30; 17.1 35; 19.9 19; 11.0 
Adjusted OR (95% CI); p-value 2.52 (1.84 to 3.46); <0.01 4.49 (2.90 to 6.95); <0.01 1.27 (0.86 to 1.88); 0.19 0.71 (0.43 to 1.16); 0.15 
     
Abnormal (n=15,456)     
Crude overall n; % 3,142; 20.3 777; 5.0 2,171;14.0 1,039; 6.7 
Adjusted OR (95% CI); p-value 0.89 (0.82 to 0.97); 0.02 1.19 (1.00 to 1.42); 0.06 0.84 (0.76 to 0.93); <0.01 0.41 (0.37 to 0.45); 0.01 
     
Normal (n=8,690)     
Crude overall n; % 1,810; 20.8 461; 5.3 1,130; 13.0 291; 3.3 
Adjusted OR (95% CI); p-value 0.89 (0.81 to 0.98); 0.02 1.19 (0.99 to 1.43); 0.08  0.72 (0.65 to 0.81); <0.01 0.19 (0.16 to 0.22); <0.01 
Covariates: Screening round type; Sedation use; Screening centre (as a higher-level variable)
 
